The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s close on Friday, September 18, 2015: Additions: Blue Buffalo Pet Products TransUnion Ultragenyx...read more
Six companies went public in the past week, raising $1.4 billion. Half traded up 10% or more, and half had negative or no return. For the second week in a row, the general partner of a midstream natural gas pipelines MLP priced an upsized IPO above its range to become the year's largest company to go public by market cap. We also saw the ...read more
Galapagos, a Belgian biotech developing new treatments for inflammatory diseases, raised $275 million by offering 6.55 million shares (76% ADSs and 24% ordinary shares offered to European investors) at $42.05. The company expected to offer 6.03 million shares, upwardly revised from its originally planned 4.72 million shares. Galapagos will list on the NASDAQ under the symbol GLPG....read more
Nivalis Therapeutics, which is developing a complementary small molecule therapy for cystic fibrosis, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering. Nivalis lists several biotechs developing therapies for cystic fibrosis, including Galapagos (GLPG), which could raise over $250 million in its US IPO this week. The Boulder,...read more
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Renaissance IPO Index - Notice of September 2015 Quarterly Changes
The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s close on Friday, September 18, 2015: Additions: Blue Buffalo Pet Products TransUnion Ultragenyx...read more
US IPO Weekly Recap: With 6 IPOs, the year's largest company goes public
Six companies went public in the past week, raising $1.4 billion. Half traded up 10% or more, and half had negative or no return. For the second week in a row, the general partner of a midstream natural gas pipelines MLP priced an upsized IPO above its range to become the year's largest company to go public by market cap. We also saw the ...read more
Galapagos prices further upsized US listing at $42.05, raises $275 million
Galapagos, a Belgian biotech developing new treatments for inflammatory diseases, raised $275 million by offering 6.55 million shares (76% ADSs and 24% ordinary shares offered to European investors) at $42.05. The company expected to offer 6.03 million shares, upwardly revised from its originally planned 4.72 million shares. Galapagos will list on the NASDAQ under the symbol GLPG....read more
Cystic fibrosis biotech Nivalis Therapeutics files for a $60 million IPO
Nivalis Therapeutics, which is developing a complementary small molecule therapy for cystic fibrosis, filed on Wednesday with the SEC to raise up to $60 million in an initial public offering. Nivalis lists several biotechs developing therapies for cystic fibrosis, including Galapagos (GLPG), which could raise over $250 million in its US IPO this week. The Boulder,...read more